PMID- 36588561
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - The role of mitochondria-associated membranes mediated ROS on NLRP3 inflammasome 
      in cardiovascular diseases.
PG  - 1059576
LID - 10.3389/fcvm.2022.1059576 [doi]
LID - 1059576
AB  - Reactive oxygen species (ROS) metabolism is essential for the homeostasis of 
      cells. Appropriate production of ROS is an important signaling molecule, but 
      excessive ROS production can damage cells. ROS and ROS-associated proteins can 
      act as damage associated molecular pattern molecules (DAMPs) to activate the 
      NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome in 
      cardiovascular diseases. Previous studies have shown that there are connected 
      sites, termed mitochondria-associated membranes (MAMs), between mitochondria and 
      the endoplasmic reticulum. In cardiovascular disease progression, MAMs play 
      multiple roles, the most important of which is the ability to mediate ROS 
      generation, which further activates the NLPR3 inflammasome, exacerbating the 
      progression of disease. In this review, the following topics will be covered: 1. 
      Molecular structures on MAMs that can mediate ROS generation; 2. Specific 
      mechanisms of molecule-mediated ROS generation and the molecules' roles in 
      cardiovascular disease, 3. The effects of MAMs-mediated ROS on the NLRP3 
      inflammasome in cardiovascular disease. The purpose of this review is to provide 
      a basis for subsequent clinical treatment development.
CI  - Copyright (c) 2022 Zhao, Li, Li and Chen.
FAU - Zhao, Jiahao
AU  - Zhao J
AD  - Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, 
      Chengdu, China.
AD  - Regenerative Medicine Research Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Li, Junli
AU  - Li J
AD  - Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Li, Guoyong
AU  - Li G
AD  - Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, 
      Chengdu, China.
AD  - Regenerative Medicine Research Center, West China Hospital, Sichuan University, 
      Chengdu, China.
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Chen, Mao
AU  - Chen M
AD  - Laboratory of Heart Valve Disease, West China Hospital, Sichuan University, 
      Chengdu, China.
AD  - Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 
      China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221214
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9794868
OTO - NOTNLM
OT  - NLRP3 inflammasome
OT  - atherosclerosis
OT  - mitochondria-associated membranes
OT  - myocardial hypertrophy
OT  - myocardial infarction
OT  - reactive oxygen species
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/03 06:00
MHDA- 2023/01/03 06:01
PMCR- 2022/01/01
CRDT- 2023/01/02 03:35
PHST- 2022/10/01 00:00 [received]
PHST- 2022/11/01 00:00 [accepted]
PHST- 2023/01/02 03:35 [entrez]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/03 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.1059576 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2022 Dec 14;9:1059576. doi: 10.3389/fcvm.2022.1059576. 
      eCollection 2022.